23.5%) Risk of recurrence prediction was quite similar between calculated and observed. (26.7% calculated and 25.6% observed) In low risk group, FIGO stage ($p=0.004$) and old age ($p=0.04$) was related of the risk of recurrence using univariate analysis.

Conclusion* The KGOG-1024 risk assessment model accurately predicted a distant recurrence after chemoradiation in patients with locally advanced cervical cancer, especially in intermediate-risk group. The model may be helpful in identifying patients who may benefit from adjuvant systemic treatment after chemoradiation.

1169

ROBOTIC-ASSISTED LYMPHADENECTOMY IN PREGNANCY AS CERVICAL CANCER STAGING – A CASE REPORT

B Bittnerová*, R Pilka, V Staňková, M Janošik, P Dzvínčuk, R Marek. *University Hospital Olomouc, Department of Obstetrics and Gynaecology, Olomouc, Czech Republic*

10.1136/ijgc-2021-ESGO.98

Introduction/Background* Cervical cancer represents one of the most commonly diagnosed tumours in pregnancy. Robotic-assisted surgery is considered the standard method for surgical staging of cervical cancer. There is a very limited data in the available literature on the use of this method to perform lymphadenectomy in patients with cervical cancer during pregnancy. In the case report we describe the procedure of robotic pelvic lymphadenectomy in a patient with cervical cancer T1b in pregnancy.

Methodology A 43 years old nulliparous woman pregnant for the third time was referred to our department with a confirmed cervical adenocarcinoma in the 15th week of pregnancy. According to the preoperative imaging examination (pelvic MRI scan, expert sonography), she suffered from stage T1b cervical cancer. The patient preferred the continuation of the pregnancy. Informed about the associated risks, she signed an informed refusal rejecting proposed radical surgical treatment. Based on the recommendation of the multidisciplinary team of gynaecological oncology, a surgical staging procedure was indicated before possible neoadjuvant systemic therapy. The robotic-assisted laparoscopic lymphadenectomy was performed on 21.5.2020 as a surgical modality of a minimally invasive approach. The procedure was performed without any complications, blood loss was up to 20 ml. Histopathological examination excluded the cancer dissemination into the lymph nodes. Subsequently, systemic treatment (cisDDP + Paclitaxel) was administered for 9 cycles to ensure adequate foetal maturity. Planned caesarean sections combined with a radical surgical treatment – radical hysterectomy and bilateral adnexectomy – were performed in gestational age 30 weeks and 5 days.

Result(s)* According to definitive histology and after the neoadjuvant treatment the stage of the disease was classified as FIGO IA1 ypT1a1 ypN0 ypMX Mandard TRG3. A close follow-up is ongoing in the patient.

Conclusion* In pregnant patients with cervical cancer, robot-assisted laparoscopic lymphadenectomy is a very gentle and effective method of staging.

Diagnostics

133

ACCURACY OF TRANSVAGINAL/TRANSRECTAL ULTRASOUND IN PREOPERATIVE PELVIC LYMPH NODE ASSESSMENT IN CERVICAL CANCER PATIENTS

¹F Fruhauf*, ¹T Ballaschova, ²M Zikan, ¹L Dostalek, ³P Dundr, ¹D Cibula, ¹D Fischerova. ¹General University Hospital, First Faculty of Medicine, Charles University, Department of Obstetrics and Gynaecology, Prague, Czech Republic; ²Bulovka University Hospital, First Faculty of Medicine, Charles University, Department of Obstetrics and Gynaecology, Prague, Czech Republic; ³General University Hospital, First Faculty of Medicine, Charles University, Institute of Pathology, Prague, Czech Republic

10.1136/ijgc-2021-ESGO.99

Introduction/Background* The aim of the study was to evaluate diagnostic accuracy of ultrasound in preoperative assessment of pelvic lymph nodes (LNs) in cervical cancer patients.

Methodology Patients were retrospectively included if they met following inclusion criteria: 1) histologically verified cervical cancer; 2) preoperative ultrasound examination performed by one of three experienced sonographers (transvaginal or transrectal and transabdominal approach); 3) surgical lymph node staging (sentinel lymph node biopsy, SLNB and/or systematic pelvic lymphadenectomy, PLND or pelvic lymph node debulking). The final pathological examination served as the

Abstract 133 Table 1 Characterisation of study population

Characteristic	Value (N = 394) ^a
Age, median (range), years	43 (20 – 82)
BMI, median (range)	24.5 (14.1 – 44.9)
Histological type	
Squamous cell carcinoma	298 (75.6)
Adenocarcinoma	79 (20.0)
Neuroendocrine carcinoma	13 (3.4)
Other	4 (1.0)
Stage (FIGO 2009)	
IA1	18 (4.5)
IA2	15 (3.8)
IB1	236 (60.0)
IB2	44 (11.1)
IIA1	5 (1.2)
IIA2	2 (0.5)
IIB	47 (12.0)
IIIA	1 (0.3)
IIIB	3 (0.8)
IVA	2 (0.5)
IVB	21 (5.3)
Type of pelvic LN staging	
SLNB only	87 (22.1)
SLNB + PLND	241 (61.1)
PLND only	35 (8.9)
Debulking of pelvic LNs only	31 (7.9)
Pelvic LN status	
Normal	308 (78.2)
Macrometastases (± MIC ± ITC)	53 (13.5)
Micrometastases (± ITC)	23 (5.8)
Isolated tumour cells only	10 (2.5)

^aData are presented as number (percentage) of patients unless otherwise indicated.

reference standard. Lymph nodes with macrometastases (the largest diameter > 2 mm) were considered positive, while LNs with isolated tumour cells (ITC) and micrometastases (MIC) were considered negative.

Result(s)* 394 patients meeting the inclusion criteria between 2009 a 2019 were enrolled into the study. The characteristics of study population are shown in table 1. Squamous cell carcinomas were most common (298/394) and the majority of cases was represented by early stage cancers (274/394), specifically IB1 FIGO 2009 (236/394). Macrometastases in pelvic LNs were pathologically confirmed in 53 patients (13.5%) and micrometastases solely in 23 patients (5.8%). Ultrasound failed to detect pelvic lymph node macrometastases in 15 patients (3.8%) and median largest diameter of these unidentified metastases was 6 mm (range 3 – 11 mm). There were 27 false positive ultrasound findings (6.9%). Ultrasound reached sensitivity 71.7%, specificity 92.1%, PPV 58.5%, NPV 95.4% and overall accuracy 89.3%.

Conclusion* Transvaginal/transrectal ultrasound is a reliable method for preoperative assessment of pelvic LNs in cervical cancer patients. It showed similar accuracy in detection of nodal macrometastases as reported for other imaging modalities. Similarly to all imaging methods, it had low sensitivity in detection of small volume macrometastases and micrometastases.

Key words: cervical cancer, lymph nodes, ultrasound, diagnostic accuracy

Klikněte nebo klepněte sem a zadejte text.

238 THE UTILITY OF BIOMARKERS FOR OVARIAN CANCER RISK ASSESSMENT IN PRIMARY CARE: A PILOT STUDY

¹C Barr*, ²G Funston, ³D Jeevan, ³SS Sundar, ⁴LT Mounce, ⁵E Crosbie. ¹Manchester University NHS FT, Division of Gynaecology, Manchester, UK; ²University of Cambridge, Department of Public Health and Primary Care, UK; ³University of Birmingham, Institute of Cancer and Genomic Sciences, UK; ⁴University of Exeter, Institute of Health Research, UK; ⁵The University of Manchester, Division of Cancer Sciences, UK

10.1136/ijgc-2021-ESGO.100

Introduction/Background* Ovarian cancer is the leading cause of mortality from gynaecological malignancy. Survival improves with early diagnosis, however, early detection in primary care is challenging. The current blood test, cancer antigen 125 (CA125), has limited sensitivity and specificity for early disease. Human Epididymis 4 (HE4) is a promising diagnostic biomarker. We aimed to investigate the diagnostic accuracy and clinical utility of serum HE4 in a symptomatic primary care population.

Methodology We conducted a prospective observational study testing HE4 on primary care serum CA125 samples from women with suspected ovarian cancer in Manchester, UK, between April 2018 and April 2019. Serum HE4 was measured using chemiluminescent enzyme immunoassays following routine CA125 testing for clinical care. HE4 thresholds of 77pmol/L and 150pmol/L were used. The primary outcome was final diagnosis within 12 months of testing. Clinical outcomes were collected from hospital electronic patient records. Receiver operator characteristic (ROC) curves with area under the curve (AUC), sensitivity and specificity were calculated for CA125 and HE4 both alone and in combination. Age adjusted HE4 thresholds were calculated with linear regression models.

Result(s)* 1247 patients were included, with a mean age of 50 years (SD 15.7). 100 women had epithelial ovarian cancer; including 82 invasive and 18 borderline ovarian tumours. There was little difference in overall performance of CA125 and HE4 (AUC 0.932 vs 0.914 respectively). At a threshold of 77pmol/L, HE4 alone had a better sensitivity than CA125 [89% (95%CI 81.2-94.4) vs 81% (95% CI 71.9-88.2)] but a worse specificity [75.6% (95%CI 73-78) vs 92.2% (95%CI 90.4-93.6)]. HE4 and CA125 combined had improved sensitivity compared with CA125 alone (93%, 95%CI 86.1-97.1), but at a significant cost to specificity (70%, 95%CI 67.3-72.6). Serum HE4 levels were correlated with increasing age ($p < 0.001$) and worsening eGFR ($p < 0.001$). Age adjusted HE4 cut-offs marginally improved the specificity of CA125, however the numbers were small per age category and require validation in larger cohorts.

Conclusion* HE4 adds little to current diagnostic pathways in primary care. Age-adjusted thresholds may improve accuracy, but not sufficiently to recommend routine use at present.

433 MYOMETRIAL INFILTRATION ASSESSMENT IN LOW-RISK ENDOMETRIAL CANCER BY 3D TRANSVAGINAL ULTRASOUND AND DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING

¹N Carreras Diéguez*, ²M Munmany, ³C De Guirior, ¹P Fusté, ³I Matas, ¹B Díaz-Feijoo, ¹AG Glickman, ⁴L Buñesch, ¹N Agustí, ³C Ros, ⁴M Sebastià, ¹M Del Pino, ⁵A Saco, ⁴C Nicolau, ³J Ordi, ¹A Torne. ¹Hospital Clínic de Barcelona, Gynaecologic Oncology Unit, Barcelona, Spain; ²Hospital Clínic de Barcelona, Gynaecology, Obstetrics and Neonatology, Barcelona, Spain; ³Hospital Clínic de Barcelona, Gynaecology, Obstetrics and Neonatology, Barcelona, Spain; ⁴Hospital Clínic de Barcelona, Radiology, Barcelona, Spain; ⁵Hospital Clínic de Barcelona, Pathology Department, Barcelona, Spain

10.1136/ijgc-2021-ESGO.101

Introduction/Background* In patients with early-stage, grade 1-2, endometrioid endometrial cancer, preoperative assessment of myometrial invasion is essential to define the need of pelvic and paraaortic lymph node dissection. Our aim was to evaluate the role of three-dimensional transvaginal ultrasound (3D-TVUS) and diffusion-weighted magnetic resonance imaging (DW-MRI) for the assessment of myometrial infiltration in patients with well-differentiated (G1) or moderately differentiated (G2) endometrioid endometrial carcinoma (EC).

Methodology We performed a retrospective observational study. Myometrial infiltration was assessed by 3D-TVUS and DW-MRI in 152 women with G1 or G2 endometrioid EC who underwent surgical treatment in a tertiary referral center between 2012 and 2019. Sensitivity, specificity, predictive values and accuracy for the two techniques and for a combination of both were computed. Definitive histopathological data in the surgical specimen regarding myometrial infiltration was used as 'Gold Standard'.

Result(s)* One hundred and fifty-two patients were included, 120 (79%) patients presented myometrial infiltration <50% in postoperative analysis of surgical specimen and 32 (21%) patients presented deep myometrial infiltration (>50%). 3D-TVUS and DW-MRI showed an agreement of 78.9% with a kappa index of 0.44 for the detection of deep myometrial infiltration. Sensitivity, specificity and accuracy of 3D-TVUS for the detection of deep myometrial infiltration were 71.0%, 80.5% and 78.5% respectively. Evaluation of myometrial